American Healthcare REIT, Inc. (NYSE:AHR – Get Free Report) Director Jeffrey Hanson sold 35,570 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $48.38, for a total transaction of $1,720,876.60. Following the sale, the director directly owned 19,208 shares of the company’s stock, valued at approximately $929,283.04. This trade represents a 64.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
American Healthcare REIT Trading Up 0.7%
Shares of AHR opened at $48.28 on Tuesday. American Healthcare REIT, Inc. has a 12 month low of $26.40 and a 12 month high of $51.01. The stock’s 50-day moving average is $47.79 and its two-hundred day moving average is $42.65. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.44 and a quick ratio of 0.44. The stock has a market cap of $8.54 billion, a PE ratio of 344.82, a P/E/G ratio of 2.00 and a beta of 0.93.
American Healthcare REIT Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Wednesday, December 31st will be given a $0.25 dividend. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $1.00 annualized dividend and a yield of 2.1%. American Healthcare REIT’s dividend payout ratio (DPR) is 714.29%.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of research firms recently weighed in on AHR. Citigroup raised their price target on shares of American Healthcare REIT from $45.00 to $52.00 and gave the company a “neutral” rating in a report on Friday, November 21st. Morgan Stanley upped their price objective on shares of American Healthcare REIT from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, November 20th. UBS Group lifted their target price on American Healthcare REIT from $51.00 to $56.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Truist Financial boosted their price target on American Healthcare REIT from $46.00 to $53.00 and gave the stock a “buy” rating in a research note on Wednesday, November 26th. Finally, Zacks Research upgraded American Healthcare REIT from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $51.64.
Read Our Latest Report on American Healthcare REIT
American Healthcare REIT Company Profile
American Healthcare REIT, Inc (NYSE: AHR) was a publicly traded real estate investment trust focused on acquiring, owning and managing healthcare‐related properties across the United States. The company’s portfolio spanned senior housing communities, skilled nursing facilities, medical office buildings and outpatient care centers, all operated under long‐term net lease or triple‐net lease structures designed to provide stable, predictable rental income.
Employing a strategy of partnering with established healthcare operators, American Healthcare REIT targeted properties in both major metropolitan areas and high‐growth secondary markets to capitalize on demographic trends such as an aging population and increased demand for outpatient services.
See Also
- Five stocks we like better than American Healthcare REIT
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Your “birthright claim” just got activated
- Wall Street Stockpicker Names #1 Stock of 2026
- Turn your “dead money” into $306+ monthly (starting this month)
Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
